Table 2.

Summary of findings from studies reporting on weight

Outcome (units)	Study author, year	Intervention	Sample size	Results
				Intervention	Control	p value
RCTs
% patients with >10% increase above BL	Jatoi et al., 2002 42	2.5 mg dronabinol capsules b.i.d.	I: 152 C: 159	Self‐reported 3, physician‐reported 5	Self‐reported 11, physician‐reported 14	0.02, 0.009
% patients with a max weight gain of 0%, 1–4%, 5–9% or >10%				65, 23, 8, & 3	57, 23, 10, & 10	0.041
Mean change in body weight, kg (SD)	Turcott et al., 2018 43	0.5 mg nabilone for 2 weeks, then 1 mg for 6 weeks	I: 14 C: 19	−1.4 (1.6)	−1.09 (2.6)	0.724
NRSI
Percent % change, range	Bar‐Sela et al., 2019 44	Cannabis capsules 10 mg THC:CBD (9.5:0.5) or 5 mg THC:CBD (4.75:0.25) q.d. for 2 weeks then b.i.d. (morning, then +8 h)	11	7.7–21.6	None	Not reported
Mean BL and final weight, kg (SD) Mean weight change, kg	Kasvis et al., 2019 45	medical cannabis treatment based on individual assessment by multidisciplinary team	37	BL: 70.7 (19.3) Final: 66.1 (23.0) Calculated from mean BL and final weight: −4.6	None	0.509
Mean BL and final weight, kg (SD) Mean weight change, kg	Kasvis et al., 2019 46	cannabinoid therapy (# of participants): THC/CBD (1:1) (6 total) THC‐rich (17 total) CBD‐rich (0 total) combined therapies (# of participants): THC/CBD and THC‐rich (17 total) THC/CBD and CBD‐rich (7 total) THC‐ and CBD‐rich (17 total) THC/CBD, THC‐rich, CBD‐rich (1 total)	54 (51 included in analysis)	BL: 70.7 (14.6) Final: 71.0 (14.8) Calculated from mean BL and final weight: 0.3	None	Not reported
Median weight change, kg (range)	Nelson et al., 1994 47	THC 2.5 mg p.o. t.i.d. 1 h post‐meals	6	1.3 (1.0–2.7)	None	Not reported
Descriptive weight change, n		2.5 mg b.i.d. for 3 days if >65 years		3 gained weight 2 maintained a stable weight 1 lost weight	None	N/A
Median rate of weight loss before and after therapy, kg/months	Plasse et al., 1991 23	I: dronabinol treatment, 4 groups; group 1: 2.5 mg q.d. group 2: 2.5 mg b.i.d. group 3: 5 mg q.d. group 4: 5 mg b.i.d. Study 1: group 3 received dose before breakfast; Study 2: group 3 received dose before dinner;	42	Before I: group 1: −3.2 group 2: −3.2 group 3: −1.5 group 4: −1.1 After I: group 1: −2.3 group 2: −1.5 group 3: −1.4 group 4: 0.2	None	Group 1 and group 3 only: <0.05
Median weight gain, kg (range)	Walsh et al., 2005 48	7.5 to 15 mg dronabinol q.d. in 5 patients, 1 patient remained on initial dose	5	1 (0.5)	None	Not reported
Individual patient weight change, patient #, kg			6	1: +1 2: 0 3: n/a (withdrew) 4: +5 5: +1 6: +3	None	Not reported

Abbreviations: b.i.d., twice daily; C, comparison; CBD, cannabidiol; CE, cannabis extract; F/U, follow up; I, intervention; NRSI, non‐randomized study of intervention; q.d., daily; RCT, randomized controlled trial; SC, synthetic cannabinoid; SD, standard deviation; THC, tetrahydrocannabinol; t.i.d., three times daily.